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Background: Pelvic organs morbidity after irradiation of cancer patients remains a major
problem although new technologies have been developed and implemented. A relatively
simple and suitable method for routine clinical practice is needed for preliminary assess-
ment  of normal tissue intrinsic radiosensitivity. The micronucleus test (MNT) determines
the frequency of the radiation induced micronuclei (MN) in peripheral blood lymphocytes,
which could serve as an indicator of intrinsic cell radiosensitivity.
Aim: To investigate a possible use of the micronucleus test (MNT) for acute radiation mor-
bidity prediction in gynecological cancer patients.
Materials and methods: Forty gynecological cancer patients received 50 Gy conventional exter-
nal  pelvic irradiation after radical surgery. A four-ﬁeld “box” technique was applied with 2D
planning. The control group included 10 healthy females.
Acute normal tissue reactions were graded according to NCI CTCAE v.3.0. From all reaction
scores, the highest score named “summarized clinical radiosensitivity” was selected for a
statistical analysis.
MNT was performed before and after in vitro irradiation with 1.5 Gy. The mean radiation
induced frequency of micronuclei per 1000 binucleated cells (MN/1000) and lymphocytes
containing micronuclei per 1000 binucleated cells (cells with MN/1000) were evaluated for
both  patients and controls.
An arbitrary cut off value was created to pick up a radiosensitive individual: the meanvalue of spontaneous frequency of cells with MN/1000 ± 2SD, found in the control group.
Both  mean spontaneous frequency of cells with MN/1000 and MN/1000 were registered to
be  signiﬁcantly higher in cancer patients compared to the control group (t = 2.46, p = 0.02 and
t  = 2.51, p = 0.02). No statistical difference was registered when comparing radiation induced
MN  frequencies between those groups.
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Eighty percent (32) of patients developed grade 2 summarized clinical radiosensitivity, with
great  variations in MNT parameters. Only three patients with grade 2 “summarized clin-
ical radiosensitivity” had values of cells with MN/1000 above the chosen radiosensitivity
threshold.
Conclusion: The present study was not able to conﬁrm in vitro MNT applicability for radiosen-
sitivity prediction in pelvic irradiation.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
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i. Background
he contemporary radiotherapy aims at achieving local tumor
ontrol with contribution to the overall survival with a good
uality of life.
The effects in early responding tissues are a very important
ssue in radiotherapy.1,2
Normal tissue intrinsic radiosensitivity is the main limiting
actor for total irradiation dose in clinical practice deﬁning a
ormal tissue tolerance to irradiation.3–5
Pelvic organs morbidity after irradiation of cancer patients
emains a major problem, although new technologies have
een developed and implemented.
A relatively simple and suitable method for routine clinical
ractice is needed for preliminary assessment of normal tis-
ue intrinsic radiosensitivity. It would allow individualization
f radiotherapy dose applying higher dose in radioresistant
atients to achieve a potentially better local tumor control of
p to 20%.1,6
Multiple studies have shown that normal tissue morbidity
fter irradiation in cancer patients correlates with radiosen-
itivity of skin ﬁbroblasts and peripheral blood lymphocytes
f these patients. This ﬁnding stimulates the search of prog-
ostic criteria for evaluating the intrinsic individual cellular
adiosensitivity.1,3,7
The micronucleus test (MNT) determines the frequency of
he radiation induced micronuclei (MN) in peripheral blood
ymphocytes, which could serve as an indicator of intrinsic
ell radiosensitivity.
After mutagen attack, MN  in interphase cells are formed
y mitotic loss of acentric fragments or chromosomes which
re not incorporated in the daughter cell nuclei.8 Because of
ts reliability and easy performance, MNT  could be a promis-
ng method for evaluating normal tissue morbidity in cancer
atients during radiotherapy1 with results yielded in less than
 weeks.
The in vitro radiation response of the peripheral blood
ymphocytes correlates with the in vivo response.7,9 Human
ymphocytes from peripheral blood could be easier to collect
ith results faster to obtain. Besides, the method is easily
eproducible, which makes it a preferred modality in assessing
he normal tissue radiosensitivity.1,8,10 Some studies on can-
er patients show the association of increased radiosensitivity
ith side effects.1,10 Study of prostate cancer patients showed
ssociation between the frequencies of ex vivo induced MN
efore the beginning of radiotherapy and gastrointestinal and
enitourinary side effects.11 So, there are convincing and log-
cal evidence for using radiation changes in the peripheralz.o.o. All rights reserved.
blood lymphocytes in the Go phase as a quick prognostic
biomarker for normal tissue morbidity.
In the search for the best model for clinical radiosensitivity
testing, cervical and endometrial cancers were found to be
very appropriate cancer localizations.
2. Aim
In an effort to ﬁnd a prognostic method for normal tissue
intrinsic radiosensitivity for patients receiving pelvic irradi-
ation, we  used the micronucleus test (MNT).
We  investigated if patients with high frequency of in vitro
radiation induced micronuclei in peripheral blood lympho-
cytes are at high risk for developing more  severe early normal
tissue adverse events after pelvic irradiation.
3.  Materials  and  methods
3.1.  Patients,  treatment  and  control  group
The study included 40 females – 23 with cervical cancer and
17 with endometrial cancer in early stage with no lymph
node metastasis present. They were recruited for the period of
2006–2008. The mean age was 57.7 ± 13.5 (range 31–75 years).
They all received adjuvant external pelvic radiotherapy after
radical gynecological surgery with a cobalt machine. The total
dose delivered was 50 Gy with 2 Gy daily fractions. A four-ﬁeld
“box” technique was applied. The 2D planning target volume
(PTV) inevitably included 2/3 of the vagina, 50% bladder and
segments from the rectum and small intestine.
We  investigated both cervical and endometrial cancer
patients together because the irradiation technique and the
PTV we applied were the same according to the treatment pro-
tocol of our department for postoperative radiotherapy in early
stage for these cancer localizations.
The patients included had no history of previous toxic
treatment or exposure.
An informed consent was obtained from every patient
before the start of treatment and the study was approved by
the local ethic committee.
A control group of 10 healthy females was used. Mean con-
trols’ age was 48.9 ± 12.6 (range 30–66). Our control group was
found to be representative when compared with a referent
control group of 57 healthy donors of the same Bulgarian lab-
oratory and we stopped recruiting more  healthy donors.12
nd ra26  reports of practical oncology a
3.2.  Normal  tissue  reactions
Acute normal tissue reactions were graded according to the
Common Terminology Criteria for Adverse Events v.3.0 of the
NCI. We worked out a radiation reaction questionnaire based
on CTCAE v.3.0 for data collecting. The patients were followed
weekly during the radiotherapy course, and in the ﬁrst and
third month after it ended for recording side effects deﬁned as
early during that period. Gastrointestinal, genitourinary and
skin side effects were observed and registered. Besides grad-
ing the adverse events from 1 to 5, for statistical evaluation
of the data, we  created an additional parameter named sum-
marized clinical radiosensitivity. It represented the highest
reaction score in any of the systems for an individual patient.
3.3. Micronucleus  assay
Two blood samples were obtained prior to the beginning of
the radiotherapy from each patient in Li-heparin vaccutain-
ers. After in vitro irradiation of each sample with 1.5 Gy of
60Co source (dose rate 1 Gy/min), the MNT  was performed on
the lymphocytes. The MN assay began within 24 h after col-
lection of blood samples. Both the irradiated and the control
blood was mixed with 5 ml  RPMI-1640 culture medium sup-
plemented with 20% calf serum and phytohemagglutinin at
2 mkg/ml ﬁnal concentration. The samples were incubated for
72 h at 37 ◦C in 5% CO2. To block the cytokinesis at 44 h cyto-
halasin B was added to produce ﬁnal concentration of 6 mkg/l.
After total incubation time of 72 h, the lymphocytes were har-
vested, they were centrifuged and ﬁxed with methanol and
acetic acid (3:1) for 15 min. The ﬁxation was done three times
and then a cell drop on dry clean slides was spread and stained
with 5% Giemsa. MN  were scored using the criteria proposed
by Fenech.13 For each patient, 2000 binucleated cells were
respectively analyzed both on the nonirradiated and irradiated
stains.
The total number of MN  and lymphocytes with one, two
and three MN  was deﬁned. The mean frequency of lympho-
cytes containing MN per 1000 binucleated cells (cells with
MN/1000) and the mean frequency of the MN per 1000 binucle-
ated cells (MN/1000) were calculated per sample. Although the
two parameters are interrelated and reﬂect the same process,
we analyzed both of them.
For both parameters we calculated: (1) the spontaneous
(baseline) frequency, (2) the frequency after in vitro irradiation
with 1.5 Gy and (3) the radiation induced frequency.
The radiation induced frequency of cells with MN/1000
and MN/1000 was deﬁned by subtracting the spontaneous
frequency from the frequency after irradiation. The same
Table 1 – Early radiation adverse events in 40 gynecological can
Adverse events 
0 
Gastrointestinal reactions 2 (5%) 
Genitourinary reactions 8 (20%) 
Skin reactions 16 (40%) 
Summarized clinical radiosensitivity 2 (5%) diotherapy 1 7 ( 2 0 1 2 ) 24–31
procedure was performed with the healthy donors’ blood sam-
ples.
An arbitrary cut off value was created to pick up a
radiosensitive individual. It consisted of the mean value of
spontaneous frequency of cells with MN/1000 ± 2-fold stan-
dard deviation, found in the control group. Such a parameter
was proposed by Scott et al.14
3.4. Statistical  analysis
Descriptive statistics was used for statistical analysis of the
clinical material, radiation adverse events and frequency of
cells with MN/1000 and MN/1000. t-Test for independent sam-
ples and one-way ANOVA and post hoc Dunnett test were
applied for evaluation of differences in the normal tissue
radiosensitivity between the groups.
4.  Results
4.1. Radiation  adverse  events
The observed acute side effects in the 40 patients are shown
in Table 1. Only 2 patients (5%) did not develop any side
effects during the treatment and the follow up period. No
severe adverse events of grade 3, 4 and 5 were recorded. The
remaining 38 patients had grade 1 and 2 reactions. Gastroin-
testinal reactions were seen in 38 women (95%), respectively
grade 1 in 17.5% and grade 2 in 77.5% which involved the loss
of appetite, nausea, vomiting, diarrhea, fecal incontinence,
abdominal pains, hemorrhoids, blood and mucus in the stool.
Grade 1 genitourinary side effects were reported by 21 patients
(52.5%), while 11 patients had grade 2 events (27.5%). The
patients complained of dysuria, polyuria, nicturia and incon-
tinence. Grade 1 and 2 skin reactions, including erythema, dry
and moist desquamation, were recorded in 11 (27.5%) and 13
(32.5%) patients, respectively.
When different normal tissue reactions in one patient
occurred, the highest score from all recorded side effects,
named “summarized clinical radiosensitivity” was selected for
statistical evaluation of the data.
We concluded that total dose of 50 Gy in the pelvis did not
cause severe adverse events – 80% (32) of patients developed
grade 2 summarized clinical radiosensitivity after pelvic irra-
diation of 50 Gy.4.2.  Micronucleus  assay
The frequency of cells with MN/1000 and MN/1000 in the con-
trol group before irradiation (spontaneous frequency), after
cer patients.
Grade according to CTCAE v.3.0
1 2 3–5
7 (17.5%) 31 (77.5%) 0 (0%)
21 (52.5%) 11 (27.5%) 0 (0%)
11 (27.5%) 13 (32.5%) 0 (0%)
6 (15%) 32 (80%) 0 (0%)
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Table 2 – Frequency of cells with MN/1000 in healthy donors group – spontaneous, after irradiation and radiation induced
frequency.
Donor number Spontaneous frequency
of cells with MN/1000
Frequency of cells with
MN/1000 after in vitro
irradiation
Radiation induced
frequency of cells with
MN/1000
1 8 76.5 68.5
2 6 83.5 77.5
3 11 84.0 73.0
4 23 146.0 123.0
5 19 103.5 84.5
6 15 117.5 103.0
7 20 99.0 79.0
8 16 112.0 96.0
9 17 104.0 87.5
10 23 106.5 83.5
Mean value ± SD 15.7 ± 5.9 103.25  ± 20 87.6 ± 16.1
Table 3 – Frequency of MN/1000 in healthy donors group – spontaneous, after irradiation and radiation induced frequency.
Donor number Spontaneous
frequency of
MN/1000
Frequency of
MN/1000 after
in vitro irradiation
Radiation induced
frequency of
MN/1000
1 8.50 83.5 75.00
2 7.00 92.0 85.00
3 11.50 94.5 83.00
4 26.50 162.5 136.00
5 20.50 113.5 93.00
6 16.50 138.0 121.50
7 23.50 112.0 88.50
8 19.50 134.5 115.00
9 16.50 117.0 100.50
10 25.00 125.0 100.00
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Fig. 1 presents data on spontaneous frequency of cells with
MN/1000 and MN/1000 of cancer patient and healthy donor
groups.Mean value ± SD 17.5 ± 6.8 
rradiation, and the radiation induced frequency are presented
n Tables 2 and 3, respectively.
The mean radiation induced frequency of cells with
N/1000 in the control group is 87.6 ± 16.1 (Table 2).
The mean radiation induced frequency of MN/1000 in the
ontrol group is 99.7 ± 19.1 (Table 3). To assess the representa-
iveness of the control group of the study we compared the
pontaneous frequency of both parameters with a referent
ontrol group of 57 healthy subjects tested in the same labora-
ory by the same method, with the following reference values:
ells with MN/1000 – 11.82 ± 6.25 and MN/1000 12.94 ± 6.99.12
here was no signiﬁcant difference in the investigated base-
ine parameters (spontaneous frequency of MN/1000 cells or
ells with MN/1000 (t-test for independent samples t = 2.089;
 = 0.066; t = 2.122; p = 0.063) between our controls and referent
ontrols.
The frequency of cells with MN/1000 and MN/1000 in
he group of 40 patients before irradiation (spontaneous fre-
uency), after irradiation, and the radiation induced frequency
re presented respectively in Tables 4 and 5.
The mean spontaneous frequency of cells with MN/1000
nd MN/1000 is respectively 21.7 ± 10 and 24.7 ± 12.2. After
ample irradiation, the mean frequency of cells with MN/1000
s 112 ± 24.6 and MN/1000 was 131.16 ± 33.5.
Tables 4 and 5 demonstrate the derivation of the two
arameters – (1) radiation induced frequency of cells with
N/1000 and (2) radiation induced frequency of MN/1000.117.25 ± 24 99.7 ± 19.1
The mean radiation induced frequency of cells with
MN/1000 of the 40 patients group is 90.3 ± 19.7.
The mean radiation induced frequency of MN/1000 of the
group of 40 patients is 106.5 ± 27.5.Fig. 1 – Spontaneous frequency of cells with MN/1000 and
MN/1000 of cancer patients and healthy donors groups
(mean value ± SEM). *Signiﬁcant difference between the
groups with degree of probability p < 0.05 (t-test).
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Table 4 – Frequency of cells with MN/1000 in patients
group – spontaneous, after irradiation and radiation
induced frequency.
Patient
number
Spontaneous
frequency of
cells with
MN/1000
Frequency of
cells with
MN/1000 after
in vitro
irradiation
Radiation
induced
frequency
of cells with
MN/1000
1 15 138.5  123.5
2 10 73 63
3 23 102.5 79.5
4 9.5 85 75.5
5 22 87 65
6 19 77 58
7 12.5 93 80.5
8 19 95 76
9 15.5 104 88.5
10 21 113 92
11 26 94 68
12 12 90.5 78.5
13 17 99.5 82.5
14 52.5 160 107.5
15 21 117.5 96.5
16 26.5 118 91.5
17 4.5 88.5 84
18 6 92.5 86.5
19 15.5 113 97.5
20 17.5 91 73.5
21 30.5 118 87.5
22 23.5 92 68.5
23 17 119 102
24 19.5 73 53.5
25 12 103.5 91.5
26 35 168.5 133.5
27 35.5 114.5 79
28 22.5 111 88.5
29 19.5 89.5 70
30 34.5 102 67.5
31 20 109 89
32 19.5 132.5 113
33 44.5 162.5 118
34 38.5 146.5 108
35 23.5 133.5 110
36 19 140.5 121.5
37 15 122 107
38 16.5 132.5 116
39 27 143 116
40 31 136 105
Table 5 – Frequency of MN/1000 in patients group –
spontaneous, after irradiation and radiation induced
frequency.
Patient
number
Spontaneous
frequency of
MN/1000
Frequency of
MN/1000 after
in vitro
irradiation
Radiation
induced
frequency of
MN/1000
1 7 162.5  155.5
2 11 80.5 69.5
3 26.5 125 98.5
4 13 104.5 91.5
5 22.5 101 78,5
6 20.5 88 67.5
7 13 104 91
8 22 111 89
9 17.5 129 111.5
10 23.5 141 117.5
11 31 96 65
12 13 101 88
13 18.5 112.5 94
14 61 217.5 156.5
15 27 137 110
16 29 134.5 105.5
17 4.5 102.5 98
18 6 104 98
19 18.5 145 126.5
20 20 109 89
21 35 131.5 96.5
22 26 101 75
23 25 130 105
24 20 79.5 59.5
25 14 112 98
26 42.5 207 164.5
27 38 132.5 94.5
28 26.5 123 96.5
29 22.5 99.5 77
30 40.5 113 72.5
31 23.5 127 103.5
32 22 155.5 133.5
33 56 194.5 138.5
34 42.5 175 132.5
35 25.5 155 129.5
36 21 162.5 141.5
37 17 142.5 125.5
38 22 164.5 142.5
39 29 173 144Mean value ± SD 21.7 ± 10 112 ± 24.6 90.3 ± 19.7
The mean spontaneous frequency of both parameters in
cancer patients (cells with MN/1000 and MN/1000) was signiﬁ-
cantly higher compared to the control group (t = 2.46, p = 0.021
and t = 2.51, p = 0.018). One-way ANOVA showed a signiﬁ-
cant effect of the factor diagnosis F (1, 38) = 4.58, p < 0.05)
only for spontaneous (non irradiated lymphocytes) frequency
MN/1000. Post hoc Dunnett test revealed that the frequency
of spontaneous MN/1000 of patients with cervical cancer was
statistically reliably lower than that of endometrial carcinoma
patients (p < 0.05).
No signiﬁcant difference was found when comparing radi-
ation induced frequency of cells with MN/1000 and MN/1000
between patient and healthy donor groups. One-way ANOVA
did not show a signiﬁcant effect of the factor diagnosis for40 37 162.5 125.5
Mean value ± SD 24.76 ± 12 131.16 ± 33.5 106.5 ± 27.5
the radiation induced frequency of cells with MN/1000 and
MN/1000.
4.3.  Selection  of  radiosensitive  individuals
The arbitrary cut off value named radiosensitivity thresh-
old is 119.9 cells with MN/1000. It is derived from the mean
value of the spontaneous frequency of cells with MN/1000 in
the observed control group 87.5 + 2 SD (2 × 16.1). This param-
eter is considered in the literature as a criterion for high
radiosensitivity14 and used by some authors.15 We  applied
the parameter “cells with MN/1000” which is considered more
suitable in evaluating a single cell death risk, while a single
MN in diploid cell correlates only with the loss of proliferative
activity.16
reports of practical oncology and rad
Fig. 2 – Radiation induced frequency of cells with MN/1000
in cancer patient, compared with summarized clinical
radiosensitivity. Straight line shows the limit set by the
mean frequency of radiation induced cells with MN/1000 of
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the control group plus twice the standard deviation (119.9).
Fig. 2 shows the values of the radiation induced frequency
f cells with MN/1000 in each patient, plotted to summarized
linical radiosensitivity. Only three patients with the high-
st grade of summarized clinical radiosensitivity in the group
grade 2) had values of cells with MN/1000 above the radiosen-
itivity threshold, respectively 123.5, 133.5 and 121.5.
Patients with grade 2 side effects showed variable values of
NT  on both parameters.
Only one of the three patients with a value of cells with
N/1000 above the radiosensitivity threshold (123.5) had
rade 2 genitourinary side effects. The patient with the value
f 121.5 cells with MN/1000 (50 years old) had grade 1 reac-
ions, while the third patient with the highest value of 133.5
70 years old) did not develop genitourinary side effects. The
ame patient had a low spontaneous frequency of cells with
N/1000 amounting to 35.
Two of the patients with values above the radiosensitiv-
ty threshold developed grade 2 skin reactions, and the third
atient did not develop any skin reactions (60 years old). To
ighlight some of the toxic agents, a correlation between
nduced frequencies of MN  in the patient group and smoking
as also investigated. No such correlation was found. We  did
ot ﬁnd smoking to affect the spontaneous cells with MN/1000
t = 0.68, p = 0.07) and MN/1000 (t = 0.72, p = 0.08).
.  Discussion
NT  is a relatively simple method and its implementation
akes several days. This makes it especially attractive and
any  authors have explored it in order to demonstrate its
apabilities for routine clinical use. In most works, the MN
ssay has been studied more  as an indicator of cell liabil-
ty in development of various malignancies – cancers of the
ead and neck, breast, lung.10 It is successfully implemented
o identify high radiosensitive breast cancer patients.17 Theseiotherapy 1 7 ( 2 0 1 2 ) 24–31 29
reasons stimulate our efforts to investigate similar association
in pelvic irradiation in cancer patients, where the gastroin-
testinal and genitourinary adverse events signiﬁcantly deplete
patients’ quality of life, compared with cosmetic skin reac-
tions in breast irradiation, assessed in the above mentioned
study.
The cohorts of patients in studies reported in the literature
are inhomogeneous. They involved patients with different
types of malignant tumors, different sizes of PTV and critical
organ volumes, different daily and total radiation doses and
techniques applied.18,19
Our study group of 40 patients was a homogeneous cohort
in terms of gender, clinical stage, previous treatment, equip-
ment, volume, fractionation and total dose of irradiation,
which is an advantage of our study compared to other studies.
We are the ﬁrst authors to use the system CTCAE 3.0 when the
MNA is applied for radiosensitivity prediction.
Most authors analyzed 100, 250, 500–1000
lymphocytes,14,18–21 especially in cases of low frequency
of MN. To increase the accuracy and obtain statistical reli-
ability of the MNT, we  examined 2000 cells of patients and
controls, both before and after irradiation,22 meeting the
recommendations for standardizing the method.23
Once we applied in vitro a test dose of 1.5 Gy aiming to
deﬁne highly radiosensitive patients prior to the beginning of
irradiation, the mean statistical difference between healthy
donors and cancer patients disappeared. The same conclusion
came from the study of Mozdarani et al., on esophageal can-
cer patients, who also reported a deletion of MN difference in
control and patients groups after in vitro irradiation.15 Some
authors, however, found such difference, which may be due
to several factors: cancer types, fractionation schedules, total
doses applied,11,19 including high-dose brachytherapy.19,20
Studying the frequency of radiation induced MN, we found
large individual variations in both the control and patient
group. This implies the existence of different individual sen-
sitivity to genotoxic agents, a difference in repair capacity
or different patient exposure to chemical genotoxic agents,
undetected in the history of controls. To outline some of the
agents, we sought correlation between the radiation induced
micronucleus frequency in the patient group and smoking.
No difference was found in both tested parameters. Probably,
that is the reason why Widel et al.20 did not analyze smok-
ing. In addition Ban et al.24 found that smoking did not affect
the spontaneous frequency of MN and cells with MN. More-
over, the results of Human MicroNucleus project also showed
no increase in MN baseline in smokers.25 Only in long active
smokers exposed to occupational genotoxic agents can signif-
icant increase in MN be seen. This shows the lack of sensitivity
of the MNT to such an important agent in society.
The criterion deﬁning a radiosensitive patient is quite ten-
tative. Fig. 2 shows a mean frequency of radiation induced cells
with MN/1000 + two times standard deviation in the control
group (95% CI). This parameter was proposed by Scott et al.
who also noted that larger groups are needed for more  precise
deﬁnition of a radiosensitivity threshold.14In our control group, the threshold of radiosensitivity was
119.9 cells with MN/1000. Applying this strongly restrictive
criterion, we  detected only three patients with values of MN
above the threshold witch had developed grade 2 early adverse
nd ra
r
1
1
1
1
1
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events (Fig. 2). Such low rate reactions could be explained with
moderate dose of 50 Gy to the pelvis organs, routinely applied
in clinical practice. We did not include patients on brachyther-
apy in the study.
Our ﬁnal analysis points out that MNT  did not interpret
radiation sensitivity explicitly.
1. After 1.5 Gy in vitro irradiation differences between con-
trols and cancer patients were erased.
2. Large inter-individual variations are observed between
patients with grade 2 side effects (ranging from 53.5 to 133
5 cells with MN/1000 and from 59.5 to 164.5 for MN/1000).
3. At the same time, there are patients who did not develop
any side effects, but had values of radiation induced MN
frequency above the mean.
Therefore, our results could not lead to recommendation of
in vitro MNT  for routine clinical use. Similar statement could
also be found in Maria Widel work, who tested 55 cervical
cancer patients, even with higher doses of up to 100 Gy after
brachytherapy.20
Doses of 45–50 Gy were routinely applied in clinical prac-
tice after radical surgery for cancer of the uterine cervix and
endometrium. They were selected after long experience with
huge number of patients in many  clinical trials. Nevertheless,
the application of these doses, tolerated by normal pelvic tis-
sues as they are, could later result in severe radiation proctitis,
colitis and cystitis in some individuals and could seriously
harm their quality of life. Individual radiosensitivity of such
patients was the target of our study aiming to ﬁnd a reliable
test with proper parameters.
6.  Conclusion
High expectations were raised over the studies for radiosensi-
tivity prediction in cancer patients aiming at individualization
of radiotherapy, prophylaxis and attenuation of adverse
events.
Large inter-individual variations in the values of sponta-
neous and radiation induced frequency of MN  were registered
in the study. They do not correspond to moderate radiation
side effects in the pelvis after application of standard doses of
50 Gy, tolerated by pelvis risk organs. The overlapping frequen-
cies of MN  parameters in patients with moderate radiation
side effects and patients with none or mild effects were sig-
niﬁcant.
The ﬁnal study analysis does not provide evidence sup-
porting direct implementation of in vitro MNT  in radiotherapy
practice for individual radiosensitivity assessment.
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